Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IQV
HOLDIQVIA Holdings Inc. · Healthcare · United States · $31.9B · Avg Vol: $312M/d
COMPANY DESCRIPTION
IQVIA Holdings Inc. is a global leader providing advanced analytics, technology solutions, and clinical research services to the life sciences industry. Its competitive moat stems from an unparalleled proprietary data estate combined with sophisticated analytics and clinical expertise, crucial for drug development and commercialization. The company is a key strategic partner for pharmaceutical and biotech firms worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.4B | 15.0B | 15.4B | 16.3B | 4.2% | 16.6B | 17.3B | 18.3B | 5.9% |
| EPS | 5.82 | 7.39 | 7.57 | 7.91 | 10.8% | 8.25 | 8.50 | 9.41 | 9.1% |
| Shares | 185.7M | 181.5M | 176.1M | 169.6M | -8.7% | 166.9M | — | — | — |
| Debt | 13.0B | 13.9B | 14.2B | 15.9B | 7.0% | 16.2B | — | — | — |
| Equity | 5.8B | 6.1B | 6.1B | 6.5B | 4.1% | — | — | — | — |
| Op CF | 2.3B | 2.1B | 2.7B | 2.7B | 5.5% | 2.7B | — | — | — |
| Inv CF | -2.0B | -1.6B | -1.4B | -2.3B | — | — | — | — | — |
| Fin CF | -329.0M | -382.0M | -878.0M | -150.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IQV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IQV | IQVIA Holdings Inc.(you) | $31.9B | 65 | HOLD |
| A | Agilent Technologies, Inc. | $32.5B | 68 | BUY |
| WAT | Waters Corporation | $36.8B | 61 | HOLD |
| IDXX | IDEXX Laboratories, Inc. | $43.5B | 59 | HOLD |
| NTRA | Natera, Inc. | $37.5B | 53 | HOLD |
| RVTY | Revvity, Inc. | $12.6B | 67 | BUY |
| ILMN | Illumina, Inc. | $26.7B | 82 | STRONG BUY |
| CRL | Charles River Laboratories International, Inc. | $10.4B | 66 | BUY |
| MEDP | Medpace Holdings, Inc. | $15.1B | 75 | BUY |
| GH | Guardant Health, Inc. | $19.8B | 47 | HOLD |
Peer medians: ROE -22.1% · P/E 27.3x · Gross margin 49.2%